BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22642896)

  • 1. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.
    Singh RR; Bains A; Patel KP; Rahimi H; Barkoh BA; Paladugu A; Bisrat T; Ravandi-Kashani F; Cortes JE; Kantarjian HM; Medeiros LJ; Luthra R
    J Mol Diagn; 2012 Jul; 14(4):336-45. PubMed ID: 22642896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
    Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
    Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of screening method for DNMT3A mutations by high-resolution melting analysis in acute myeloid leukemia.
    Mizuta S; Yamane N; Komai T; Koba Y; Kawata T; Ukyo N; Tamekane A; Watanabe M
    Int J Lab Hematol; 2019 Oct; 41(5):593-600. PubMed ID: 31149783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of High-Resolution Melting (HRM) Analysis with Direct Sequencing for the Detection of DNMT3A Mutations in AML Patients.
    Moonesi M; Zaka Khosravi S; Moradabadi A; Rajaeinejad M; Heidari MF; Mahjub G; Noroozi-Aghideh A
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2185-2190. PubMed ID: 35901322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
    Mechaal A; Menif S; Abbes S; Safra I
    Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
    Alpermann T; Schnittger S; Eder C; Dicker F; Meggendorfer M; Kern W; Schmid C; Aul C; Staib P; Wendtner CM; Schmitz N; Haferlach C; Haferlach T
    Haematologica; 2016 Feb; 101(2):e55-8. PubMed ID: 26471486
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking the gold standard for recurrent DNA mutations detection in acute myeloid leukemia.
    Novaretti MC
    Eur J Haematol; 2016 Feb; 96(2):109-10. PubMed ID: 26110968
    [No Abstract]   [Full Text] [Related]  

  • 13. Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.
    Eisfeld AK; Kohlschmidt J; Mrózek K; Blachly JS; Nicolet D; Kroll K; Orwick S; Carroll AJ; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Leukemia; 2016 Nov; 30(11):2254-2258. PubMed ID: 27435003
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.
    Wakita S; Yamaguchi H; Omori I; Terada K; Ueda T; Manabe E; Kurosawa S; Iida S; Ibaraki T; Sato Y; Todoroki T; Hirakawa T; Ryotokuji T; Arai K; Kitano T; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2013 Apr; 27(5):1044-52. PubMed ID: 23135354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effective screening of DNMT3A coding sequence identifies somatic mutation in pediatric T-cell acute lymphoblastic leukemia.
    Szarzyńska-Zawadzka B; Kosmalska M; Sędek Ł; Sonsala A; Twardoch M; Kowalczyk JR; Szczepański T; Witt M; Dawidowska M
    Eur J Haematol; 2017 Dec; 99(6):514-519. PubMed ID: 28905428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.
    Gale RE; Lamb K; Allen C; El-Sharkawi D; Stowe C; Jenkinson S; Tinsley S; Dickson G; Burnett AK; Hills RK; Linch DC
    J Clin Oncol; 2015 Jun; 33(18):2072-83. PubMed ID: 25964253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    PLoS One; 2011; 6(10):e26906. PubMed ID: 22066015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.